Home › Funds › Redmile Group, LLC › XENE
Redmile Group, LLC position in XENE
XENON PHARMACEUTICALS INC · Health Care
Redmile Group, LLC reported holding 229,374 shares of XENE (XENON PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$13.8M, representing 0.93% of its reported portfolio and ranking #23 among its reported holdings. Redmile Group, LLC has disclosed XENE holdings in 4 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Redmile Group, LLC's XENE position evolved
Redmile Group, LLC first disclosed a stake in XENE in Q3 2023 at 419,568 shares (US$14.3M). The position peaked in Q1 2026 at 262,674 shares, worth US$15.3M. Across 4 filings, Redmile Group, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 229,374 shares valued at US$13.8M — a reduction of -33,300 shares quarter over quarter.. Notable position changes include a 96% increase in Q1 2026 (shares rose 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 419.57K | $14.33M | New |
| Q4 2025 | 133.88K | $6.00M | New |
| Q1 2026 | 262.67K | $15.27M | Add |
| Q2 2026 | 229.37K | $13.85M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About XENE and 13F data
XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 44 other funds we track also report a position in XENE — the largest reported positions include Avoro Capital Advisors LLC (US$348.7M), Polar Capital Holdings Plc (US$275.9M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$266.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding XENE
- Avoro Capital Advisors LLC 5.78M sh · $348.75M · Q2 2026
- Polar Capital Holdings Plc 4.57M sh · $275.88M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 4.42M sh · $266.70M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.62M sh · $97.52M · Q2 2026
- Affinity Asset Advisors, LLC 1.59M sh · $96.27M · Q2 2026
- Siren, L.L.C. 1.32M sh · $79.59M · Q2 2026
- BRAIDWELL LP 1.13M sh · $68.29M · Q2 2026
- ORBIMED ADVISORS LLC 892.47K sh · $53.87M · Q2 2026
- Caligan Partners LP 889.94K sh · $53.72M · Q2 2026
- Caption Management, LLC 728.00K sh · $43.94M · Q2 2026
- Vestal Point Capital, LP 700.00K sh · $42.25M · Q2 2026
- Rock Springs Capital Management LP 683.91K sh · $41.28M · Q2 2026
More on Redmile Group, LLC
FAQ
How long has Redmile Group, LLC held XENE?
Redmile Group, LLC has disclosed XENE holdings in 4 of the last 12 reported quarters, going back to Q3 2023.
What is Redmile Group, LLC's current position in XENE?
As of Q2 2026, Redmile Group, LLC holds 229.37K shares of XENE (XENON PHARMACEUTICALS INC), valued at $13.85M, representing 0.93% of its reported portfolio and ranking #23.
Has Redmile Group, LLC been buying or selling XENE?
In the latest 13F filing (Q2 2026), Redmile Group, LLC reduced its position in XENE. The position peaked in Q1 2026 at 262.67K shares.
Which other funds hold XENE?
Other major institutional holders of XENE include Avoro Capital Advisors LLC, Polar Capital Holdings Plc, DRIEHAUS CAPITAL MANAGEMENT LLC, among 44 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.